COVID-19 and diabetes: What do we know so far?-Reference-Cited by-同舟云学术

COVID-19 and diabetes: What do we know so far?

Published:2022-07-27 Issue:15 Volume:247 Page:1330-1334
ISSN:1535-3702
Container-title:Experimental Biology and Medicine
language:en
Short-container-title:Exp Biol Med (Maywood)

Author:

Gangadaran Prakash¹²^ORCID,Padinjarathil Himabindu³⁴,Rajendran Shri Hari Subhashri⁵,Jogalekar Manasi P⁶^ORCID,Hong Chae Moon²,Aruchamy Baladhandapani³⁴,Rajendran Uma Maheswari⁷,Gurunagarajan Sridharan⁸,Krishnan Anand⁹,Ramani Prasanna³⁴^ORCID,Subramanian Kavimani⁵

Affiliation:

1. BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

2. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea

3. Dhanvanthri Lab, Department of Sciences, Amrita School of Physical Sciences, Amrita Vishwa Vidyapeetham, Coimbatore 641112, India

4. Center of Excellence in Advanced Materials & Green Technologies (CoE-AMGT), Amrita School of Engineering, Amrita Vishwa Vidyapeetham, Coimbatore 641112, India

5. Department of Pharmacology, College of Pharmacy, Mother Theresa Postgraduate and Research Institute of Health Sciences, Puducherry 605006, India

6. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA

7. ICMR-Vector Control Research Centre, Puducherry 605006, India

8. Department of Biochemistry, Srimad Andavan Arts and Science College, Bharathidasan University, Trichy 620005, India

9. Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa

Abstract

Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.

Publisher

SAGE Publications

Subject

General Biochemistry, Genetics and Molecular Biology

Link

http://journals.sagepub.com/doi/pdf/10.1177/15353702221108914

Reference51 articles.

1. Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions

2. SARS-CoV-2 variants: A double-edged sword?

3. A mini-review on the effects of COVID-19 on younger individuals

4. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

5. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of inflammation in determining the severity of COVID-19 infection in patients with diabetes: A comparative study;Medicine;2023-12-15

2. CuFe2O4 Magnetic Nanoparticles as Heterogeneous Catalysts for Synthesis of Dihydropyrimidinones as Inhibitors of SARS-CoV-2 Surface Proteins—Insights from Molecular Docking Studies;Processes;2023-07-31

3. Analysis and Validation of Planar Microwave Diagonal Stub Loaded Closed Loop Resonator for Glucose Monitoring;2022 URSI Regional Conference on Radio Science (USRI-RCRS);2022-12-01